Pleura, Chest Wall, Lung, and Mediastinum

Chapter

Abstract

An objective approach to the surgical palliation of pleural, pulmonary, and mediastinal malignancy with a focus on minimally invasive, low-morbidity techniques

References

  1. 1.
    Wildgaard K, Ravn J, Kehlet H. Chronic post-thoracotomy pain: a critical review of pathogenic mechanisms and strategies for prevention. Eur J Cardiothorac Surg. 2009;36(1):170–80.PubMedCrossRefGoogle Scholar
  2. 2.
    Heffner JE. Diagnosis and management of malignant pleural effusions. Respirology. 2008;13:5–20.PubMedCrossRefGoogle Scholar
  3. 3.
    Bernard A, de Dompsure RB, Hagry O, et al. Early and late mortality after pleurodesis for malignant pleural effusion. Ann Thorac Surg. 2002;74:213–7.PubMedCrossRefGoogle Scholar
  4. 4.
    Dresler CM, Olak J, Herndon II JE, et al. Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909–15.PubMedCrossRefGoogle Scholar
  5. 5.
    Stefani A, Natali P, Casali C, Morandi U. Talc poudrage versus talc slurry in the treatment of malignant pleural effusion. A prospective comparative study. Eur J Cardiothorac Surg. 2006;30(6):827–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Lee P. Should thoracoscopic talc pleurodesis be the first choice management for malignant effusion? Yes. Chest. 2012;142(1):15–7.PubMedGoogle Scholar
  7. 7.
    Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med. 1994;120:56–64.PubMedCrossRefGoogle Scholar
  8. 8.
    Tan C, Sedrakyan A, Browne J, et al. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardiothorac Surg. 2006;29:829–38.PubMedCrossRefGoogle Scholar
  9. 9.
    Colt HG, Davoudi M. The ideal pleurodesis agent: still searching after all these years. Lancet Oncol. 2008;9:912–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Efthymiou CA, Masudi T, Thorpe JA, Papagiannopoulos K. Malignant pleural effusion in the presence of trapped lung. Five-year experience of PleurX tunneled catheters. Interact Cardiovasc Thorac Surg. 2009;9(6):961–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Fysh ET, Waterer GW, Kendall P, Bremner P, Dina S, Geelhoed E, et al. Indwelling pleural catheters reduce inpatient days over pleurodesis for malignant pleural effusion. Chest. 2012;142(2):394–400.PubMedCrossRefGoogle Scholar
  12. 12.
    Davies H, Mishra E, Wrightson J, Stanton A. The second therapeutic intervention in Malignant Effusion Trial (TIME2): a randomized controlled trial to assess the efficacy and safety of patient controlled malignant pleural effusion by indwelling pleural catheter compared to chest tube and Talc Slurry. Am J Respir Crit Care Med. 2012;185:6860.Google Scholar
  13. 13.
    Tsao AS, Witsuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol. 2009;27:2081–90.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaufman AJ, Flores RM. Surgical treatment of malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:201–16.PubMedCrossRefGoogle Scholar
  15. 15.
    Kindler HL. Surgery for mesothelioma? The debate continues. Lancet Oncol. 2011;12:713–4.PubMedCrossRefGoogle Scholar
  16. 16.
    Rice D. Surgical therapy of mesothelioma. Recent results. Cancer Res. 2011;189:97–125.Google Scholar
  17. 17.
    Maziak DE, Gagliardi A, Haynes AE, et al. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer. 2005;48:157–69.PubMedCrossRefGoogle Scholar
  18. 18.
    Rice D, Rusch V, Passh H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol. 2011;6:1304–12.PubMedCrossRefGoogle Scholar
  19. 19.
    Tsao S, Witsuba I, Hasani A, Alvarez JM, Wyatt JM, et al. Outcome for patients with malignant pleural mesothelioma referred for tri-modality therapy in Western Australia. J Thorac Oncol. 2009;4:1110–6.Google Scholar
  20. 20.
    Thomford N, Woolner L, Clagett O. The surgical treatment of metastatic tumors in the lungs. J Thorac Cardiovasc Surg. 1965;49:357–63.PubMedGoogle Scholar
  21. 21.
    Roth J, Pass H, Wesley M, White D, Putnam I. Comparison of median sternotomy and thoracotomy for resection of pulmonary metastases in patients with adult soft-tissue sarcomas. Ann Thorac Surg. 1986;42:134–8.PubMedCrossRefGoogle Scholar
  22. 22.
    Vogt-Moykopf I, Krysa S, Bülzebruck H, Schirren J. Surgery for pulmonary metastases. The Heidelberg experience. Chest Surg Clin N Am. 1994;4:85–112.PubMedGoogle Scholar
  23. 23.
    Pfannschmidt J, Hoffmann H, Dienemann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol. 2010;5(6 Suppl 2):S172–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Neeff H, Hörth W, Makowiec F, Fischer E. Outcome after resection of hepatic and pulmonary metastases of colorectal cancer. J Gastrointest Surg. 2009;13:1813–20.PubMedCrossRefGoogle Scholar
  25. 25.
    Meimarakis G, Angele M, Schneider C, Weidenhagen R, Kalaitzis N, Molki A, et al. Bedeutung der systematischen Lymphknoten-dissektion im Rahmen der Resektion pulmonaler Metastasen solider extrapulmonaler Tumoren. Zentralbl Chir. 2010;135:556–63.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Cardiothoracic Surgery UnitRoyal Adelaide HospitalNorth Terrace, AdelaideAustralia

Personalised recommendations